Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.
The introduction of acellular pertussis vaccines has greatly enhanced the safety profile of vaccines to prevent whooping cough. Pertussis toxin (Ptx) is one component produced by Bordetella pertussis that is contained in all of these vaccines, either in combination with other known pertussis virulence factors or as the sole pertussis component, combined with tetanus and diphtheria toxoids. A hydrogen peroxide toxoid of Ptx has been shown to be efficacious in preventing pertussis infections in a mass vaccination trial and is presently licensed in the United States and Europe (B. Trollfors, J. Taranger, T. Lagergard, L. Lind, V. Sundh, G. Zackrisson, C. U. Lowe, W. Blackwelder, and J. B. Robbins, N. Engl. J. Med. 333:1045-1050, 1995). The industrial production of Ptx can be performed through the cultivation of B. pertussis in well-defined growth media, in which the components can be well characterized and their origins can be documented. Once the bacteria are removed from the culture, Ptx can be isolated from the supernatant and purified by using the technique described by Sekura et al. (R. D. Sekura, F. Fish, C. R. Manclark, B. Meade, and Y. L. Zhang, J. Biol. Chem. 258:14647-14651, 1983). The only drawback of this procedure, which combines two affinity chromatography steps, one with Blue Sepharose and a second with matrix-bound bovine fetuin (BF), is the source and purity of the BF. Concern about vaccine preparations that may possibly risk contamination by material associated with bovine spongioform encephalopathy has continued to increase. We thus sought a replacement for the BF affinity chromatography and, more specifically, for the glycosidic moiety on BF. We describe here the identification of a seven-amino-acid peptide that mimics the glycosidic moiety on BF to which Ptx binds. Furthermore, we have constructed an affinity column containing this peptide that can be used to replace BF in Ptx purification. Finally, we used the X-ray crystallographic structure of Ptx bound to the oligosaccharide moiety of BF as a scaffold and replaced the oligosaccharide with the peptide.
Bogdan
John A
JA
Baxter Healthcare Corporation, Columbia, Maryland 21046, USA. jbogdan@niaid.nih.gov
Yuan
Wei
W
Long-Rowe
Karen O
KO
Sarwar
Jawad
J
Brucker
Eric Allen
EA
Blake
M S
MS
D000595:Amino Acid Sequence; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D001665:Binding Sites; D001886:Bordetella pertussis / Q000276:immunology / Q000378:metabolism; D016466:CHO Cells; D002417:Cattle; D002846:Chromatography, Affinity / Q000379:methods; D006224:Cricetinae; D018360:Crystallography, X-Ray; D006801:Humans; D008958:Models, Molecular; D018716:Molecular Mimicry; D008969:Molecular Sequence Data; D019151:Peptide Library; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D037342:Pertussis Toxin / Q000737:chemistry* / Q000276:immunology / Q000302:isolation & purification*; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology; D014917:Whooping Cough / Q000517:prevention & control; D000509:alpha-Fetoproteins / Q000737:chemistry*
D000907:Antibodies, Bacterial; D019151:Peptide Library; D010455:Peptides; D010567:Pertussis Vaccine; D000509:alpha-Fetoproteins; D037342:Pertussis Toxin